Moleculin Biotech, Inc. reported on January 7, 2026, that it has regained compliance with Nasdaq's minimum stockholders’ equity requirement of $2.5 million, following a delisting notification received on November 20, 2025, which has now resulted in the cancellation of a scheduled hearing.